As Seen In

As Seen In
Stockhouse: RepliCel Hits Lucrative Bio-med Trifecta with Innovative Tech
To read the article on Stockhouse click here Until 2011, RepliCel Life Sciences (TSX: V.RP,...
As Seen In
The Province: Four Biotech Companies that are Helping B.C. Lead the Battle Against Aging
To read the full article on The Province newspaper website click here\n\nA Vancouver-based anti-aging company...
As Seen In
Financial Post: Seeking to Cure the Incurable
To read the article on the Financial Post website click here.\n\nCanada and Japan are taking...
As Seen In
Streetwise Report Interviews BioWatch News Founder Alan Leong
To read the full report, click here. Biotechnology can be daunting to comprehend, but understanding...
As Seen In
The Total Tutor Interviews CEO David Hall on BlogTalkRadio
RepliCel’s CEO David Hall is interviewed by The Total Tutor Neil Haley on blogtalkradio. Hall...
As Seen In
Houston Style Magazine Interviews RepliCel CEO
 New Treatment for NFL Players and Pro Athletes Offers New HopeStory by: Jo-CarolynNew York, NY,...
As Seen In
CEO David Hall Interviewed on ESPN New York Radio
To listen to the full interview, click here or view the file below. CEO &...
As Seen In
VP Lee Buckler Podcast Interview by Midas Letter
Written By: James West Listen to the full interview here. RepliCel’s VP Lee Buckler explains...
As Seen In
Chronic Achilles Tendinosis Video Launched
Using Your Own Cells to Heal Tendon InjuriesRepliCel is developing an autologous cell-based product for...
As Seen In
November 7, 2014 – R. Lee Buckler: How RepliCel is Harnessing the Awesome Power of Cell Therapy
To read the full report, click here: R. Lee Bucker on RepliCel Life SciencesRegenerative medicine...
As Seen In
Midas Letter Interviews CEO David Hall
To listen to the full interview podcast and read the transcript click here: Midas Letter...
As Seen In
Japan Gives a Hug to the Cell Therapy Industry: R. Lee Buckler
To read the full report click here: R. Lee Buckler on the Cell Therapy IndustryLast...
As Seen In
Seeking Alpha – Why RepliCel is a Promising Under-Researched Small-Cap Biotech
By: Eric Chiu, Biotech, Healthcare Contributor Published October 10, 2014To read the entire article as...
As Seen In
Seeking Alpha Article – RepliCel Offers Significant Upside
To view the article as it appears on Seeking Alpha, click here.Summary  RepliCel is a...
As Seen In
September 9th, 2014- Featured in the Financial Post: New Technology Puts Your Own Cells to Work to Repair and Rejuvenate Your Body
To read the full report click here: RepliCel’s Cutting-Edge Advancements   The following has been published...
As Seen In
September 9th, 2014- RepliCel marches ahead with cell therapy trials
New in BioWorld, the latest in RepliCel’s cell therapy trials and what they could mean...
As Seen In
August 7, 2014 – Mark Landy from Summer Street Research Partners Comments on RepliCel in August’s issues of The Life Sciences Report
To read the full report click here: Mark Landy on New Growth Ideas for Biotech...
As Seen In
BioWatch News – RepliCel as a Featured Company in June’s Issue Exploring Alopecia and its Industry
Cell therapies for curing alopecia are early in their clinical development. These must still show...
As Seen In
July 10, 2014 – Alan Leong from BioWatch News Comments on RepliCel in July’s Issues of The Life Sciences Report
For the full article click here: Alan Leong Interview on Niche Biotech Prospects life-scineces-report Read...
As Seen In
Yahoo Sports Article – RepliCel interviewed on Cristiano Ronaldo’s obscure injury could open door for U.S.
By Martin Rogers June 8, 2014 11:14 PM Yahoo Sports SAO PAULO – To a...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.